|
1) 中野孝司. ピットフォール悪性胸膜中皮腫. 呼吸. 2009; 28: 509-15
|
|
|
|
2) 樋野興夫. 遺伝子診断 中皮腫の遺伝子マーカー. 日本臨牀. 2008; 66: 241-5
|
|
|
|
|
|
3) Robinson BW, Lake RA. Advances in malignant mesothelioma. N Engl J Med. 2005; 353: 1591-603
|
|
|
|
|
4) 廣島健三. 組織診断 悪性中皮腫の病理診断. 日本臨牀. 2008; 66: 374-8
|
|
|
|
|
|
5) 井内康輝, 武島幸男, 櫛谷 桂. 胸膜中皮腫の病理学鑑別診断と免疫組織化学染色の有用性. In: 岸本卓己, 編. 胸膜中皮腫診療ハンドブック. 東京: 中外医学社; 2007. p. 100-10
|
|
|
|
|
|
6) Herndon JE, Green MR, Chahinian AP, et al. Factors predictive of surviving among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B. Chest. 1998; 113: 723-31
|
|
|
|
|
|
7) 岸本卓己, 玄馬顕一, 西 英行, 他. 胸膜中皮腫の診断と治療. 日本肺癌学会雑誌. 2008; 48: 165-70
|
|
|
|
|
|
8) Petterson T, Froseth B, Riska H, et al. Concent-ration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest. 1988; 94: 1037-9
|
|
|
|
|
|
9) 高橋和久. 呼吸器疾患におけるオステオポンチンの役割. 呼吸. 2005; 24: 222-31
|
|
|
|
|
|
10) Pass HI, Lott D, Lonardo F, et al. Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med. 2005; 353: 1564-73
|
|
|
|
|
|
11) Grigoriu BD, Scherpereel A, Devos P, et al. Utility of osteopontin and serum mesothelin in malig-nant pleural mesothelioma diagnosis and prog-nosis assessment. Clin Cancer Res. 2007; 13: 2928-35
|
|
|
|
|
|
12) Scholler N, Fu N, Yang Y, et al. Soluble mem-ber(s) of the mesothelin/megakaryocyte poten-tiating factor family are detectable in sera from patients with ovarian carcinoma. Proc Natl Acad Sci U S A. 1999; 96: 11531-6
|
|
|
|
|
|
13) Hassan R, Bera T, Pastan I. Mesothelin: a new target for immunotherapy. Clin Cancer Res. 2004; 10(12Pt 1): 3937-42
|
|
|
|
|
|
14) Scherpereel A, Lee YC. Biomarkers for meso-thelioma. Curr Opin Pulm Med. 2007; 13: 339- 443
|
|
|
|
|
|
15) Kojima T, Oh-eda M, Hattori K, et al. Molecular cloning and expression of megakaryocyte potentiating factor cDNA. J Biol Chem. 1995; 270: 21984-90
|
|
|
|
|
|
16) Hino O, Kobayashi E, Nishizawa M, et al. Renal carcinogenesis in the Eker rat. J Cancer Res Clin Oncol. 1995; 121: 602-5
|
|
|
|
|
|
17) Shiomi K, Miyamoto H, Segawa T, et al. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci. 2006; 97: 928-32
|
|
|
|
|
|
18) Shiomi K, Hagiwara Y, Sonoue K, et al. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma. Clin Cancer Res. 2008; 14: 1431-7
|
|
|
|
|
|
19) Iwahori K, Osaki T, Serada S, et al. Megakaryo-cyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer. 2008; 62: 45-54
|
|
|
|
|
|
20) Schouwink H, Korse CM, Bonfrer JM, et al. Prognostic value of the serum tumour markers Cyfra21-1 and tissue polypeptide antigen in malignant mesothelioma. Lung Cancer. 1999; 25: 25-32
|
|
|
|
|
|
21) Cristaudo A, Foddis R, Vivaldi A, et al. Clinical significance of serum mesothelin in patients with mesothelioma and lung cancer. Clin Cancer Res. 2007; 13: 5076-81
|
|
|
|
|
|
22) Beck A, Ivanova A, Ivanov S, et al. Evaluation of plasma osteoponitn as early detection and prognosis marker in malignant pleural meso-thelioma. J Clin Oncol. 2008; 26(suppl 15): 238
|
|
|
|
|
|
23) Creaney J, Yeoman D, Naumoff LK, et al. Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax. 2007; 62: 569-76
|
|
|
|
|
|
24) Baldi A, Santini D, Vasaturo F, et al. Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cyclin inhibitors p21 and p27 in human pleural malignant mesothelioma. Thorax. 2004; 59: 428-33
|
|
|
|
|
|
25) Tajima K, Hirama M, Shiomi K, et al. ERC/mesothelin as a marker for chemotherapeutic response in patients with mesothelioma. Anticancer Res. 2008; 28: 3933-6
|
|
|
|
|
|
26) Greillier L, Baas P, Welch JJ, et al. Biomarkers for malignant pleural mesothelioma. Current Status. Mol Diag Ther. 2008; 12: 375-90
|
|
|
|
|
|
27) Scherpereel A, Grigoriu B, Conti M, et al. Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med. 2006; 173: 1155-60
|
|
|
|
|
|
28) Pass HI, Wali A, Tang N, et al. Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg. 2008; 85: 265-72
|
|
|
|
|